Philip Morris International (PM) Q1 2025: Smoke-Free Portfolio Delivers 44% of Gross Profit, Margin Expansion Accelerates
Philip Morris International (PM) posted a robust Q1 2025, driven by double-digit growth in its smoke-free portfolio, which now accounts for 44% of total gross profit and delivered significant margin expansion. Strong ZYN, nicotine pouch, and IQOS, heated tobacco unit, momentum offset geographic mix pressure in combustibles, enabling operating income to rise 16% organically and adjusted EPS to climb 17% in constant currency. Management raised full-year ZYN shipment guidance and reaffirmed double-digit EPS growth, signaling ongoing confidence in its multi-category transformation despite macro and regulatory headwinds.
Summary
- Smoke-Free Profit Surge: Smoke-free products delivered 44% of gross profit, with organic net revenue up 20% and gross profit up 33% YoY.
- ZYN and IQOS Expansion: ZYN shipments in the US rose 53% YoY, while IQOS volumes grew nearly 10% globally despite regulatory flavor bans.
- Margin Expansion Momentum: Gross margin for smoke-free products surpassed 70%, widening the gap over combustibles and driving operating income growth.
- Raised Guidance on Strength: Management lifted ZYN shipment forecasts and maintained double-digit EPS growth outlook, reflecting confidence in category leadership and execution.
Performance Analysis
Philip Morris International delivered organic net revenue growth of 10.2% to $9.3 billion in Q1 2025, with volume up 3.9% and adjusted diluted EPS rising 17.3% in constant currency to $1.69. Smoke-free products—including IQOS, ZYN, and VEEV, e-vapor—drove the quarter, with shipment volumes up 14.4% and organic gross profit up 33%, reflecting both scale and favorable mix.
Combustible (traditional cigarette) revenue and gross profit grew 3.8% and 5.3% organically, respectively, aided by strong pricing but offset by negative geographic mix as volumes increased in lower-margin markets like Turkey and Egypt. Gross margin expanded by 340 basis points organically, underpinned by smoke-free mix and pricing, while SG&A growth was in line with investments in US and global smoke-free expansion.
- ZYN US Outperformance: ZYN shipments reached 202 million cans, up 53%, exceeding expectations and prompting a full-year guidance raise.
- IQOS Momentum: IQOS HTU shipments grew nearly 10% globally, with Europe and Japan both delivering strong growth despite flavor ban headwinds.
- Profitability Shift: Smoke-free gross margin now exceeds 70%, over 5 points higher than combustibles, materially improving overall margin structure.
PMI’s multi-category strategy is delivering both top-line and margin expansion, with smoke-free products now at the center of profit generation and future growth.
Executive Commentary
"Our smoke-free business performed exceptionally well across all areas with shipment volumes up plus 14.4% year-on-year, organic net revenue growth of plus 20%, and outstanding organic growth profit growth of plus 33%, as all three smoke-free categories expanded gross margin. This was especially fueled by the rapid growth of ZYN and the continued volume momentum, operating leverage, and scale benefit of IQOS."
Emmanuel Barbot, Chief Financial Officer
"We now forecast double-digit adjusted diluted EPS growth at prevailing exchange rates. While it is early in the year and there are a number of uncertainty in the global economic outlook, we remain confident that we will achieve another year of super growth."
Emmanuel Barbot, Chief Financial Officer
Strategic Positioning
1. Multi-Category Transformation Accelerates
PMI’s transition from combustibles to smoke-free products is now the core value driver. The company’s multi-category strategy—leveraging IQOS, ZYN, and VEEV—has built a diversified, higher-margin portfolio. Smoke-free now represents 44% of gross profit, up sharply from prior years, and PMI is present in 46 markets with multiple smoke-free offerings, 16 of which offer all three categories. This breadth is creating positive mix effects and deepening competitive moat.
2. ZYN US Leadership and Supply Chain Execution
ZYN, nicotine pouch, is the fastest-growing profit contributor in the US, with shipments up 53% YoY and category share above 70% despite supply constraints. PMI accelerated capacity expansion at its Kentucky plant, raising full-year shipment guidance to 800–840 million cans, and expects full normalization of supply by Q3. Ongoing investments in US manufacturing and marketing position ZYN for continued category leadership.
3. IQOS Global Growth and Regulatory Navigation
IQOS, heated tobacco unit, delivered nearly 10% shipment growth globally, with strong underlying demand in Europe and Japan. The business weathered regulatory flavor bans, particularly in Europe, by launching new variants and leveraging commercial partnerships. PMI continues to invest in device innovation (e.g., Illuma Eye), and expects double-digit IQOS growth for the remainder of 2025 as regulatory impacts annualize and new markets open.
4. Margin Structure Transformation
Smoke-free gross margin exceeded 70%, a 670-basis-point gain YoY, and now sits more than five points above combustibles. ZYN’s best-in-class unit economics, IQOS scale, and pricing power are driving this structural shift. PMI expects to maintain a material margin gap between smoke-free and combustibles, enabling sustainable EPS growth as the portfolio mix continues to shift.
5. Combustibles: Resilience and Value Maximization
Combustible volumes were positive for the fourth consecutive quarter, aided by share gains in markets where smoke-free is not permitted. However, the business faces ongoing volume declines in mature markets and negative mix from growth in lower-margin geographies. PMI’s strategy centers on value maximization and stable share, with continued pricing initiatives to offset volume headwinds.
Key Considerations
PMI’s Q1 2025 marks an inflection where smoke-free products are not only driving growth but are rebalancing the company’s margin and profit structure. Investors should focus on:
- Smoke-Free Operating Leverage: Rapid growth in ZYN and IQOS is raising overall profitability, with scale and mix effects accelerating margin expansion.
- Supply Chain Normalization: ZYN supply constraints are easing, with full normalization expected by Q3, unlocking further retail and commercial momentum.
- Regulatory Adaptation: PMI’s ability to navigate flavor bans and regulatory shifts, especially in Europe and the US, is critical to sustaining smoke-free growth.
- Capital Allocation Discipline: Ongoing deleveraging, $2 billion cost savings target (2024–2026), and a progressive dividend policy reinforce shareholder return priorities.
- Macro and Currency Volatility: Currency headwinds and global economic uncertainty remain watchpoints, though PMI’s diversified portfolio and hedging provide partial offsets.
Risks
PMI faces ongoing regulatory risk, particularly from evolving flavor bans and nicotine regulations in key markets. Macroeconomic volatility and currency swings could impact reported results despite hedging efforts. Execution risk remains in scaling supply and marketing for ZYN and IQOS, while combustible volumes are likely to decline in mature markets, testing the resilience of the legacy portfolio.
Forward Outlook
For Q2 2025, PMI guided to:
- IQOS HTU shipment volume of 37.5–38.5 billion units
- Strong IQOS adjusted IMS growth of around 10%
- US ZYN shipments at similar levels to Q1 as restocking continues
- Adjusted diluted EPS of $1.80–$1.85, including a $0.06 currency benefit
For full-year 2025, management:
- Raised ZYN shipment guidance to 800–840 million cans
- Maintained organic net revenue growth of 6–8%
- Maintained organic operating income growth of 10.5–12.5%
- Maintained currency-neutral adjusted diluted EPS growth of 10.5–12.5%
- Raised adjusted EPS forecast to $7.36–$7.49, including a $0.10 currency benefit
Management expects continued double-digit smoke-free shipment growth, further margin expansion, and steady deleveraging toward a 2x target by end of 2026.
Takeaways
PMI’s Q1 2025 demonstrates a pivotal shift as smoke-free products become the primary profit engine, with scale and mix effects accelerating margin expansion and supporting robust earnings growth.
- Smoke-Free Profit Engine: ZYN and IQOS are now driving both growth and margin, with ZYN supply normalization set to unlock further upside in the US.
- Margin Structure Realignment: The smoke-free portfolio’s 70%+ gross margin is transforming PMI’s profitability profile and enabling sustainable EPS growth.
- Execution Watchpoint: Investors should monitor ZYN retail momentum, regulatory developments, and the pace of IQOS innovation as key drivers for the remainder of 2025.
Conclusion
Philip Morris International’s Q1 2025 results confirm the company’s smoke-free transformation is not only on track but accelerating, with ZYN and IQOS driving both top-line and margin expansion. Management’s raised guidance and continued investment in innovation and supply chain signal confidence in sustaining leadership and delivering on its progressive dividend and growth commitments.
Read-Through
PMI’s results underscore the accelerating shift in global tobacco toward non-combustible, higher-margin products. The company’s ability to drive both volume and profit growth in smoke-free categories, while navigating regulatory headwinds, sets a new benchmark for the industry. Competitors in nicotine, tobacco, and adjacent wellness categories should note the critical importance of supply chain agility, multi-category diversification, and regulatory adaptation. PMI’s margin expansion and capital allocation discipline also highlight the value of structural transformation in legacy consumer goods businesses facing secular decline in core products.